ENTITY
Akeso Biopharma Inc

Akeso Biopharma Inc (9926 HK)

211
Analysis
Health CareChina
Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide
more
19 Dec 2022 08:00

Hong Kong Connect Flows (Dec 16th): Meituan, Tencent, China Mobile

We analyzed the Hong Kong Connect Scheme for last week and highlight inflows for Meituan, Tencent, and outflows from China Mobile.

Logo
449 Views
Share
13 Dec 2022 08:50

Akeso Biopharma (9926.HK) - Behind the Deal with Summit: A Snake Swallows an Elephant?

The deal between Akeso and Summit set a new record of China license-out. We deep dive the logic of the deal. Investors are advised not to neglect...

Logo
425 Views
Share
11 Dec 2022 09:01

China Healthcare Weekly (Dec.9) - COVID Policy Update, Biotech Growth Curve, HKEX Chapter 18A Review

China further optimized COVID policy, so as to release risks in advance and recover ASAP. The growth curve of biotech is not linear. We reviewed...

Logo
362 Views
Share
bullishRemegen
04 Dec 2022 09:26

China Healthcare Weekly (Dec.2)- VBP Correction, Sales Ability Overweigh R&D, Expectation Difference

VBP renewal of coronary stents shows the government will correct the underpricing;Only if sales ability is verified can biotech has better...

Logo
441 Views
Share
bearish3D Medicines
02 Dec 2022 11:06

Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation

The overall quality/core competitiveness of 3D Medicines isn't high. Its pipeline is mainly based on license-in model, which is not favored by Mr....

Logo
451 Views
Share
x